Advertisement

Blut

, Volume 60, Issue 4, pp 219–222 | Cite as

Toxicity of novel anthracycline derivatives towards normal myeloid bone marrow progenitor cells (CFU-GM) is not increased by verapamil

  • F. W. Busch
  • U. Schmittele
  • G. Ehninger
Original article

Summary

Drug-induced myelotoxicity is usually the dose-limiting factor of treatment of malignant tumors with cytostatic drugs. Suppression of in vitro myelopoiesis (CFU-GM) by cytostatics may be a suitable model reflecting the in vivo situation. Thus the inhibitory effects of the anthracyclines doxorubicin, theprubicin, idarubicin and cytorhodin S on CFU-GM were compared. Normal human bone marrow cells were incubated with these drugs for one hour and alternatively, for the whole culture period. For each substance and each incubation time a dose-response curve was established and the D50 determined. As certain calcium antagonists can increase the toxicity of some cytostatic drugs in various tumor models, the effect of the addition of verapamil (2µM) was also investigated. It could be shown, that the myelotoxicity on CFU-GM of the drugs mentioned above was not increased after short-term or permanent exposure to this calcium antagonist.

Key words

Anthracyclines Verapamil Bone marrow progenitors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Berman E, Wittes RE, Leyland-Jones B, Casper ES, Gralla RJ, Howard J, Williams L, Baratz R, Young CW (1983) Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer. Cancer Res 43: 6096–6101Google Scholar
  2. 2.
    Busch FW, deVos S, Flehmig B, Herrmann F, Sandler Ch, Vallbracht A (1987) Inhibition of in vitro hematopoiesis by hepatitis A virus. Exp Hematol 15: 978–982Google Scholar
  3. 3.
    Durie BGM, Dalton WS (1988) Reversal of drug-resistance in multiple myeloma with verapamil. Br J Haematol 68: 203–206Google Scholar
  4. 4.
    Fine RL, Koizumi S, Curt GA, Chabner BA (1987) Effect of calcium channel blockers on human CFU-GM with cytotoxic drugs. J Clin Oncol 5: 489–495Google Scholar
  5. 5.
    Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE (1983) Plasma pharmacokinetics of adriamycin and adriamycinol: Implications for the design of in vitro experiments and treatment protocols. Cancer Res 43: 3417–3421Google Scholar
  6. 6.
    Hill BT, Dennis LY, Li XT, Whelan RDH (1985) Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro. Cancer Chemother Pharmacol 14: 194–201Google Scholar
  7. 7.
    Krishan A, Sauerteig A, Gordon K, Swinkin C (1986) Flow cytometric monitoring of cellular anthracycline accumulation in murine leukemic cells. Cancer Res 46: 1768–1773Google Scholar
  8. 8.
    Mergenthaler H-G, Brühl P, Ehninger G, Heidemann E (1987) Comparative in vitro toxicity of mitoxantrone and adriamycin in human granulocyte-macrophage progenitor cells. Cancer Chemother Pharmacol 20: 8–12Google Scholar
  9. 9.
    Miller AA, Schmidt CG (1987) Clinical pharmacology and toxicity of 4′-0-tetrahydropyranyladriamycin. Cancer Res 47: 1461–1465Google Scholar
  10. 10.
    Ozols RF, Cunnion RE, Klecker RW Jr, Hamilton TC, Ostchega Y, Parrillo JE, Young RC (1987) Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5: 641–647Google Scholar
  11. 11.
    Rogan AM, Hamilton TC, Young RC, Klecker RW Jr, Ozols RF (1984) Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994–996Google Scholar
  12. 12.
    Sahar E, Michalevicz R, Broudo I, Seligsohn U (1986) Quantitation by flow cytometry of anthracycline drug uptake by peripheral blood and bone marrow cells in human leukemias. Exp Hematol 14: 119–125Google Scholar
  13. 13.
    Scott CA, Westmacott D, Broadhurst MJ, Thomas GJ, Hall MJ (1986) 9-Alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures. Br J Cancer 53: 595–600Google Scholar
  14. 14.
    Smith MA, Merry S, Smith JG, Kaye SB (1988) Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP-16. Br J Cancer 57: 576–578Google Scholar
  15. 15.
    Tsuruo T, Iida H, Yamashiro M, Tsukagoshi S, Sakurai Y (1982) Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P 388 leukemia and its sublines resistant to vincristine and adriamycin. Biochem Pharmacol 31: 3138–3140Google Scholar
  16. 16.
    Yalowich JC, Zucali JR, Gross MA, Ross WE (1985) Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K 562 leukemia cells in vitro. Cancer Res 45: 4921–4924Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • F. W. Busch
    • 1
  • U. Schmittele
    • 1
  • G. Ehninger
    • 1
  1. 1.Medizinische UniversitätsklinikTübingenGermany

Personalised recommendations